Peptide record

TPDB03687

Antibacterial Anticancer Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB03687
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia CancerPPD 2.0
standard
No
A 13-aa standard-residue multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3, Peptipedia, and CancerPPD 2.0, with an available 3D structural model.
Sequence
VRRFPWWYPFLRR
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C94H131N27O15
ANDCEQGHIKMST
R
1879.25
12.40
4
0
7
+4
3.10
-0.823
52.31
Mammalian: 100 hour Yeast: >20 hour E.coli: >10 hour
12490
6.65
1
Residue Composition
number
0
A
4
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
1
L
0
K
0
M
2
F
2
P
0
S
0
T
2
W
1
Y
1
V
Amino Acid Distribution
A: 0 R: 4 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 1 K: 0 M: 0 F: 2 P: 2 S: 0 T: 0 W: 2 Y: 1 V: 1
Chemical Descriptors
13 reviewed residue count
C94H131N27O15 sequence-only estimate (linear, free termini)
1879.25 sequence-only estimate (linear, free termini)
12.40 sequence-only estimate (linear, free termini)
+4 sequence-only estimate (linear, free termini)
3.10 sequence-only estimate (linear, free termini)
-0.823 sequence-only estimate (linear, free termini)
Evidence Records 4 records
Evidence 1 Activity

Activity

Antibacterial

Source & Reference

NA

Other

inhibited Gram- S. typhimurium (diffusion assay) more than WT. Warning: other bacteria not tested.
Evidence 2 Activity

Activity

IC50
Toxicity
21.6 µM
Cytotoxic
IC50 | 21.6 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin. | Biochim Biophys Acta | 2020
Evidence 3 Activity

Activity

50% Hemolysis
Toxicity
>=65 µM
Hemolytic Cytotoxic
50% Hemolysis | >=65 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin. | Biochim Biophys Acta | 2020
Evidence 4 Activity

Activity

IC50
Toxicity
65 µM
Hemolytic Cytotoxic
Hemolytic_activity: RBC: IC50 ≥ 65 µM | Cytotoxicity: PBMC: IC50=21.6 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Biochim Biophys Acta Biomembr. 2020 Aug 1 1862(8):183228.